Literature DB >> 23218783

Rhabdomyolysis secondary to influenza A H1N1 vaccine resulting in acute kidney injury.

Rodrigo Barbosa Callado1, Tassia Gabrielle Ponte Carneiro, Camille Carneiro da Cunha Parahyba, Neiberg de Alcantara Lima, Geraldo Bezerra da Silva Junior, Elizabeth de Francesco Daher.   

Abstract

Influenza A infection has been described as a major viral cause of infection-induced rhabdomyolysis, but to date, only one reported case was described as having been induced by influenza vaccine. We describe a case of a man who had been using statins and developed rhabdomyolysis the day after influenza A H1N1 vaccination. A 58-year-old man was admitted at the emergency room complaining of impaired gait. The patient reported receiving influenza A H1N1 vaccine 5 days prior to the admission, with symptoms beginning the day after the inoculation. He reported ascending weakness, intense myalgia in the lower back, upper and lower limbs. The admission laboratory tests showed serum creatine phosphokinase: 7600 IU/L, creatinine: 3.0 mg/dL, urea: 185 mg/dL, aspartate aminotransferase: 592 IU/L, alanine aminotransferase: 630 IU/L, potassium: 5.4 mEq/L, lactate dehydrogenase: 2828 IU/L. Despite intravenous fluid therapy, the patient still persisted with oliguria and urinary output of 0.17 ml/kg/h. Hemodialysis was initiated and renal function recovery was observed after two weeks. The patient was hemodynamically stable and asymptomatic at hospital discharge. This is a rare side effect of influenza A H1N1 vaccine. Physicians should advise patients to seek medical care when muscle symptoms are present and consider the possibility of rhabdomyolysis due to vaccination. Trials are required to better define the incidence of this important side effect.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23218783     DOI: 10.1016/j.tmaid.2012.11.004

Source DB:  PubMed          Journal:  Travel Med Infect Dis        ISSN: 1477-8939            Impact factor:   6.211


  9 in total

1.  Rhabdomyolysis probably induced by influenza vaccine and fibrate therapy.

Authors:  Hatice Hamarat; Göknur Yorulmaz; Emel Örge Gönüllü; Ayşe Ekim
Journal:  Eur J Rheumatol       Date:  2015-06-24

2.  Recurring Weakness in Rhabdomyolysis Following Pfizer-BioNTech Coronavirus Disease 2019 mRNA Vaccination.

Authors:  Motoya Kimura; Jun-Ichi Niwa; Manabu Doyu
Journal:  Vaccines (Basel)       Date:  2022-06-11

3.  Association of Current Active Illnesses and Severe Acute Kidney Injury after COVID-19 Vaccines: A Real-World Study.

Authors:  Gang Chen; Qidong Ren; Jiannan Zhou; Yangzhong Zhou; Huiting Luo; Yining Wang; Xiaolin Li; Bin Zhao; Xuemei Li
Journal:  Vaccines (Basel)       Date:  2022-04-29

4.  Acute kidney injury after COVID-19 vaccines: a real-world study.

Authors:  Huiting Luo; Xiaolin Li; Qidong Ren; Yangzhong Zhou; Gang Chen; Bin Zhao; Xuemei Li
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

Review 5.  Secondary myopathy due to systemic diseases.

Authors:  J Finsterer; W N Löscher; J Wanschitz; S Quasthoff; W Grisold
Journal:  Acta Neurol Scand       Date:  2016-02-25       Impact factor: 3.209

6.  Rhabdomyolysis after recombinant zoster vaccination: a rare adverse reaction.

Authors:  Nishan Rajaratnam; Swati Govil; Rutwik Patel; Mohamed Ahmed; Sameh Elias
Journal:  J Community Hosp Intern Med Perspect       Date:  2021-01-26

7.  MRI Findings in Case of Post-COVID-19 Vaccination Rhabdomyolysis: A Rare Postvaccination Adverse Effect.

Authors:  Tushar M Kalekar; Radhika K Jaipuria; Rahul Srichand Navani
Journal:  Indian J Radiol Imaging       Date:  2022-07-13

8.  Rhabdomyolysis Secondary to COVID-19 Vaccination.

Authors:  Mariah Mack; Laura Nichols; Dubert M Guerrero
Journal:  Cureus       Date:  2021-05-13

9.  Rhabdomyolysis due to Trimethoprim-Sulfamethoxazole Administration following a Hematopoietic Stem Cell Transplant.

Authors:  Alexander Augustyn; Mona Lisa Alattar; Harris Naina
Journal:  Case Rep Oncol Med       Date:  2015-10-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.